

Guinea-Bissau

Population 2015

1.8 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.6 (0.91–2.4)	85 (49–129)
Mortality (HIV+TB only)	0.95 (0.79–1.1)	51 (43–61)
Incidence (includes HIV+TB)	6.9 (4.5–9.8)	373 (241–533)
Incidence (HIV+TB only)	1.8 (1.1–2.6)	97 (60–142)
Incidence (MDR/RR-TB)**	0.21 (0–0.49)	11 (0–27)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.38 (0.11–0.64)	2.3 (0.92–3.6)	2.7 (1–4.3)
Males	0.46 (0.26–0.66)	3.8 (2.6–5)	4.2 (2.8–5.6)
Total	0.83 (0.51–1.2)	6 (4.5–7.6)	6.9 (4.5–9.8)

TB case notifications, 2015	
Total cases notified	2 141
Total new and relapse	2 133
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	70%
- % pulmonary	95%
- % bacteriologically confirmed among pulmonary	74%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	31% (22–48)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.38 (0.22–0.61)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	390	26%
- on antiretroviral therapy	161	41%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			65 (0–140)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	10%	16%	208
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 17, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 15, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	81%	2 234
Previously treated cases, excluding relapse, registered in 2014	100%	1
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	40%	15
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	3.8
Funding source: 3% domestic, 41% international, 56% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically